Why the study?
Familial hyperchylomicronemia syndrome is an uncommon condition with limited literature and treatment options, particularly in pediatric patients presenting with severe hypertriglyceridemia and acute pancreatitis.
A combination of restrictive diet and lipid-lowering pharmacotherapy successfully reduced severe hypertriglyceridemia in a pediatric patient with familial hyperchylomicronemia syndrome.
Answers are grounded in this paper and cite their sources.
Highlights challenges managing pediatric familial hyperchylomicronemia; leaves open targeted therapies.
Familial hyperchylomicronemia syndrome is a monogenic autosomal recessive disorder that causes severe and refractory hypertriglyceridemia. This uncommon condition is challenging to diagnose and treat and can lead to comorbidities such as acute pancreatitis. Although treatment options are limited in the pediatric population, strict diets and treatments approved for other dyslipidemias may be implemented in familial hyperchylomicronemia syndrome, given the lack of pharmacological interventions available. We report a 14-year-old female presented to the emergency room with abdominal pain suggestive of acute pancreatitis. Biochemical analysis revealed a triglyceride value of 4260 mg/dL. Treatment for triglyceride reduction with a strict CHILD-2 triglyceride-lowering diet, insulin infusion, fibrates, and multiple plasmapheresis were initially insufficient. Primary hypertriglyceridemia was suspected, and genetic testing identified a homozygous pathogenic variant in the lipoprotein lipase gene, diagnosing familial hyperchylomicronemia syndrome. She was discharged with a maximum dose of fibrate, statin, omega-3 fatty acids, and a restrictive diet. At her 1-month and 9-month follow-ups, her triglyceride values were 756 and 495 mg/dL, respectively, without incident complications. Familial hyperchylomicronemia syndrome is an uncommon condition with limited available literature and treatment options, especially in the pediatric population. Acute pancreatitis secondary to severe hypertriglyceridemia is a condition with a high risk of mortality which requires prompt clinical suspicion and treatment.
No takes yet. Share an insight, caveat, or question.
Valenzuela‐Vallejo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: